share_log

Altimmune | 8-K: Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

SEC ·  Aug 8, 2024 11:09

Summary by Futu AI

Altimmune reported Q2 2024 financial results with $164.9M cash position as of June 30, 2024. The company recorded a net loss of $24.6M ($0.35 per share) compared to $16.1M in Q2 2023. Research and development expenses increased to $21.2M from $13.3M year-over-year, primarily due to pemvidutide development costs.Recent clinical data presentations highlighted pemvidutide's therapeutic potential, showing up to 15.6% weight loss at 48 weeks in obesity trials and superior lean mass preservation with 78.1% of weight loss from fat. The drug demonstrated significant reductions in triglycerides (55.8%), total cholesterol (20%), and liver fat content in MASH studies.The company continues enrollment in Phase 2b IMPACT trial for MASH with topline data expected in Q1 2025. An End-of-Phase 2 FDA meeting is scheduled for late Q3 2024 to discuss Phase 3 obesity trial design. Management indicated ongoing progress in discussions with potential strategic partners while planning expansion into three additional therapeutic indications.
Altimmune reported Q2 2024 financial results with $164.9M cash position as of June 30, 2024. The company recorded a net loss of $24.6M ($0.35 per share) compared to $16.1M in Q2 2023. Research and development expenses increased to $21.2M from $13.3M year-over-year, primarily due to pemvidutide development costs.Recent clinical data presentations highlighted pemvidutide's therapeutic potential, showing up to 15.6% weight loss at 48 weeks in obesity trials and superior lean mass preservation with 78.1% of weight loss from fat. The drug demonstrated significant reductions in triglycerides (55.8%), total cholesterol (20%), and liver fat content in MASH studies.The company continues enrollment in Phase 2b IMPACT trial for MASH with topline data expected in Q1 2025. An End-of-Phase 2 FDA meeting is scheduled for late Q3 2024 to discuss Phase 3 obesity trial design. Management indicated ongoing progress in discussions with potential strategic partners while planning expansion into three additional therapeutic indications.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 287

Recommended